GNMSF Stock Genmab A/S (GNMSF, $259.72) price exceeded its 50-day Moving Average on September 13, 2024

GET DAILY SIGNALS

Get AI intraday signals

GNMSF - Genmab A/S

Moving Avg. signal

View

Odds of DOWN Trend

Price: $259.72

Daily change: -$7.9 (-2.95%)

Daily volume: 1.6K

Capitalization: $16.7B

Industry: Biotechnology

GNMSF's Indicator enters downward trend

The Aroon Indicator for GNMSF entered a downward trend on October 24, 2024. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 196 similar instances where the Aroon Indicator formed such a pattern. In of the 196 cases the stock moved lower. This puts the odds of a downward move at .

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 15, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on GNMSF as a result. In of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNMSF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for GNMSF just turned positive on October 23, 2024. Looking at past instances where GNMSF's MACD turned positive, the stock continued to rise in of 55 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GNMSF advanced for three days, in of 243 cases, the price rose further within the following month. The odds of a continued upward trend are .

GNMSF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.999) is normal, around the industry mean (14.849). P/E Ratio (20.762) is within average values for comparable stocks, (95.928). Projected Growth (PEG Ratio) (0.737) is also within normal values, averaging (1.788). GNMSF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (4.943) is also within normal values, averaging (211.128).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. GNMSF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GNMSF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.